IMiD: Immunomodulatory Drug Lenalidomide (CC-5013; Revlimid) in the Treatment of Lymphoma: Insights into Clinical Use and Molecular Mechanisms
Crossref DOI link: https://doi.org/10.1007/978-3-319-75184-9_4
Published Online: 2018-04-05
Published Print: 2018
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kasi, Pashtoon Murtaza
Nowakowski, Grzegorsz S.
License valid from 2018-01-01